REPLY

Affiliations

¹ Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
² Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
³ Department of GI Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Comment

Jeffrey S Morris et al. Hepatology. 2021 Jun.

. 2021 Jun;73(6):2612.

doi: 10.1002/hep.31620. Epub 2021 May 24.

¹ Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
² Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
³ Department of GI Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

No abstract available

Comment on

HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.
Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. Morris JS, et al. Hepatology. 2021 Jun;73(6):2278-2292. doi: 10.1002/hep.31555. Epub 2021 Jun 15. Hepatology. 2021. PMID: 32931023 Free PMC article.
Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations.
Huo TI, Liu PH, Hsu CY. Huo TI, et al. Hepatology. 2021 Jun;73(6):2611. doi: 10.1002/hep.31618. Epub 2021 May 24. Hepatology. 2021. PMID: 33170973 No abstract available.

1. Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, et al. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol 2016;64:601-608.